Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Human DR5 Synthetic Peptide
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
Product Details
PEP-0021
Product Specifications
Species Reactivity
Human
Class
Synthetic
Type
Peptide
Conjugate
Form
Liquid
Concentration
200 µg/mL
Purification
purified
Storage buffer
PBS, pH 7.2, with 0.1% BSA
Contains
0.02% sodium azide
Storage conditions
-20°C
Product Specific Information
This peptide corresponds to 20 amino acids near the carboxy terminus of human DR5.
PEP-0021 can be used as a blocking peptide with polyclonal antibody PA5-19895.
Target Information
DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; Death receptor 5; dr-5; Fas-like protein; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF-related apoptosis-inducing ligand receptor 2; TRAIL receptor 2; Tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9
Gene Aliases: CD262; DR5; KILLER; KILLER/DR5; TNFRSF10B; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; UNQ160/PRO186; ZTNFR9
UniProt ID: (Human) O14763
Entrez Gene ID: (Human) 8795
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support